Speaker(s): 

Andrew Amato PharmD Candidate, Student - has nothing to disclose.

Moderator(s): 

Christopher J DeFrancesco PharmD, Geisinger - has nothing to disclose.

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

1) Define the etiology of myasthenia gravis 

2) Apply the guidelines to manage Myasthenia gravis 

3) Contrast the difference between normal treatment versus crisis treatment 

4) Identify medications to avoid 

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Christopher DeFrancesco PharmD, RPH, Anil Singh MD, Roop Parlapalli, MD, FHM, FACP, Mary Ellen Berry PA-C, and Carlena Miller CRNP have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None